This was intriguing, since the EGF pathway is among those considered dysregulated in IBD [15], PDGFα is expressed, along with its receptors, in areas of active IBD inflammation [16], FGF-2 is high in the serum of subjects with CD and correlates with bowel wall thickness [17], and ANGPT1 serum levels decrease upon treatment with anti-TNFα in CD patients who achieve remission [18]. Here, FGF2 is linked to inflammatory bowel disease.